Forte Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Forte Biosciences, Inc. (FBRX) on December 4, 2023. The report addresses a change in the company's independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance regarding the external auditor.
Material Changes
- Accountant Departure: Mayer Hoffman McCann P.C. (MHM) informed the company on July 31, 2023, that it would not stand for re-appointment for the fiscal year ending December 31, 2024.
- New Appointment: On December 4, 2023, the Audit Committee approved the appointment of KPMG LLP as the new independent registered public accounting firm for the fiscal year ending December 31, 2023.
Guidance, Outlook, and Risks
The filing states that during the fiscal years ended December 31, 2022 and 2021, and the interim period through December 4, 2023, there were no consultations with KPMG regarding accounting principles or audit opinions. Furthermore, there were no "disagreements" or "reportable events" between the company and KPMG during this period.
Investor Verification Checklist
- Verify the effective date of KPMG LLP's engagement for the 2023 fiscal year audit.
- Review the prior 8-K filed on August 4, 2023, for details on the departure of Mayer Hoffman McCann P.C.
- Confirm the absence of any undisclosed disagreements or reportable events with the new auditor.